Opinion of the Transparency Council – colecalciferolum
At its meeting on 16 September 2024, the Transparency Council adopted opinion No. 150/2024 on the inclusion in reimbursement of medicines containing the active substance colecalciferolum in terms of indications for use or dosage or mode of administration different from those specified in the Summary of Product Characteristics, i.e. chronic kidney disease.